Can-Fite BioPharma (CANF) CEO lists multiple long-dated option grants

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. executive Motti Farbstein, who serves as CEO, CFO and COO, files an initial Form 3 disclosing his holdings of stock options on the company’s ordinary shares. The filing lists several direct option grants with exercise prices ranging from $17.47 to $2,439.02 per share and expirations from 2027 through 2035. Some grants are fully vested and exercisable, while others continue to vest in scheduled quarterly installments through 2029, subject to his continued service. The options were issued under Can-Fite’s 2003, 2013 and 2023 share option plans, and for Israeli tax purposes are registered in the name of a trustee.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Farbstein Motti

(Last) (First) (Middle)

C/O CAN-FITE BIOPHARMA LTD.

26 BEN GURION STREET

(Street)

RAMAT GAN 5257346

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Can-Fite BioPharma Ltd. [ CANF ]

3a. Foreign Trading Symbol
[CANF.TA]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, CFO and COO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(2)	03/28/2017	12/28/2027	Ordinary Shares	83(2)	$2,439.02(3)	D
Options to Purchase Ordinary Shares(1)(2)	01/07/2019	01/07/2029	Ordinary Shares	50(2)	$2,274.99(4)	D
Options to Purchase Ordinary Shares(1)(2)	08/27/2020	05/27/2030	Ordinary Shares	333(2)	$242.64(5)	D
Options to Purchase Ordinary Shares(1)(2)	04/13/2021	04/13/2031	Ordinary Shares	500(2)	$248.56(6)	D
Options to Purchase Ordinary Shares(1)(7)	07/17/2022	07/16/2032	Ordinary Shares	666(7)	$242.64(7)	D
Options to Purchase Ordinary Shares(1)(8)	08/01/2023	04/30/2033	Ordinary Shares	2,500(8)	$25.33(8)	D
Options to Purchase Ordinary Shares(1)(9)	08/07/2024	07/03/2034	Ordinary Shares	2,500(9)	$26.69(9)	D
Options to Purchase Ordinary Shares(1)(10)	09/24/2025	04/29/2035	Ordinary Shares	2,500(10)	$17.47(10)	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.

2. These options are fully vested and exercisable as of the date hereof.

3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 7,539, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 10, 2026, which was NIS 3.0910 = USD 1.00.

4. The exercise price of this option, originally denominated in NIS in the amount of NIS 7,032, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 10, 2026, which was NIS 3.0910 = USD 1.00.

5. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 10, 2026, which was NIS 3.0910 = USD 1.00.

6. The exercise price of this option, originally denominated in NIS in the amount of NIS 768.30, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 10, 2026, which was NIS 3.0910 = USD 1.00.

7. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 582 options are vested, and the remaining 84 options vest in two equal quarterly installments beginning 04/17/2026 and ending 07/17/2026 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

8. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,718 options are vested, and the remaining 782 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

9. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,093 options are vested, and the remaining 1,407 options vest in nine equal quarterly installments beginning 07/03/2026 and ending 07/03/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

10. The exercise price of this option, originally denominated in NIS in the amount of NIS 54, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 156 options are vested, and the remaining 2344 options vest in fifteen equal quarterly installments beginning 12/30/2025 and ending 06/30/2029 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Motti Farbstein	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Motti Farbstein’s Form 3 for Can-Fite (CANF) disclose?

The Form 3 discloses that Motti Farbstein holds several direct options to purchase Can-Fite ordinary shares. These option grants span exercise prices from $17.47 to $2,439.02 and have expiration dates between 2027 and 2035, reflecting long-term incentive awards.

What roles does Motti Farbstein hold at Can-Fite (CANF)?

The filing identifies Motti Farbstein as CEO, CFO and COO of Can-Fite BioPharma Ltd. Concentrating these three top executive roles in one individual underscores his central operational and financial responsibility within the company’s leadership structure.

How are Motti Farbstein’s Can-Fite (CANF) options structured and vested?

The options are issued under Can-Fite’s 2003, 2013 and 2023 Share Option Plans. Certain option grants are already fully vested, while others vest in quarterly installments through dates such as 07/03/2028 and 06/30/2029, conditioned on his continued service.

Why are Can-Fite (CANF) options held via a trustee under Israeli law?

To qualify for specific tax benefits under Section 102 of the Israeli Tax Ordinance, employee securities from Can-Fite’s option plans must be registered in a trustee’s name. This structure is tax-driven but the Form 3 still attributes the economic interest to the reporting person.

What currency details are disclosed for Can-Fite (CANF) option exercise prices?

The exercise prices were originally denominated in New Israeli Shekels (NIS) and are presented in U.S. dollars using Bank of Israel exchange rates around March 10–11, 2026. Footnotes specify the NIS amounts and the applied conversion rates for each grant.

Do all of Motti Farbstein’s Can-Fite (CANF) options vest immediately?

No. Footnotes state some options are fully vested and exercisable, while others vest over time. For example, one grant has 1,718 options vested and 782 vesting in five quarterly installments through 04/01/2027, contingent on continued service to the company.